About ChromoTrax

ChromoTrax is an international biomedical research and development company dedicated to developing innovative technologies and products to improve diagnosis and treatment of patients suffering from genetic-based diseases including cancers. The company’s name, ChromoTrax, reflects the functions of its core technologies - detecting chromosome aberrations through use of colors. The Company possesses two proprietary technologies: Repeat Sequence Deplete DNA probes (ReSeD), and Hybridization in Suspension (informally called Cyto-Flo). Both technologies are fully developed: ReSeD is ready for commercial sales, and Cyto-Flo is in clinical validation stage.

ChromoTrax has successfully completed Phase I and Phase II Small Business Innovation Research grants (SBIRs) from the Department of Defense, a Phase I SBIR from National Cancer Institute (NCI) for the development of its proprietary Hybridization in Suspension technology and its applications to cancer detection. The Company has also received support from Maryland TEDCO in the form of Maryland Technology Transfer Funding, as well as from the Frederick County Small Business Revolving Loan Fund.

ChromoTrax is currently located at the Frederick Innovative Technology Center in Frederick, Maryland.